Allinaire Awarded $1.9M in Grant Funding

CLEVELAND and INDIANAPOLIS, September 19, 2017 – Allinaire Therapeutics has been awarded a $1,670,000 Phase II SBIR grant from the National Heart, Lung, and Blood Institute (NHLBI) and a $213,000 Discovery Award from the Department of Defense (DOD). 

The funding will support the development of a novel therapeutic for the treatment of respiratory disorders, including acute lung injury; Alpha-1 antitrypsin deficiency and chronic obstructive pulmonary disease (COPD).

Allinaire was formed by BioMotiv, a biotech accelerator that is associated with the Harrington Project for Discovery & Development, Indiana University Research & Technology Corp (IURTC), BioCrossroads, and Innovate Indiana.  The company’s lead project is based on technology exclusively licensed from IURTC.

Read full press release here

Take a Deep Breath for an IU Pulmonary Biotech Start-Up

Breathing easy isn't just a euphemism for calming down and taking it easy. It's also the goal of a biotech start-up, Allinaire Therapeutics, which plans to use research from Indiana University School of Medicine to develop new therapies for Chronic Obstructive Pulmonary Disease, or COPD.

Read More